Inspire Medical Systems, Inc.
No SEC Form 4 filings for $INSP in the last 30 days.
See all $INSP insider activity →Inspire Medical Systems (INSP) stock rose 7.4% after Stifel raised its price target to $80.00, citing positive sentiment. Shares later cooled to $70.71, up 3.8%. The company's shares are volatile, with significant moves tied to regulatory changes and analyst upgrades. INSP is down 23.4% YTD and 50.9% off its 52-week high.
Inspire Medical Systems (NYSE:INSP), Cybin (NASDAQ:HELP), and Aveanna Healthcare (NASDAQ:AVAH) are flagged as overbought with RSI values above 70. INSP reported strong Q2 results and raised FY26 guidance, while AVAH received an Overweight rating and higher price target from Barclays. All three stocks showed significant gains over the past month.
Inspire Medical Systems (INSP) reported Q2 2026 adjusted EPS of $0.14, beating estimates, and raised its 2026 revenue and earnings guidance. Despite U.S. coding and reimbursement challenges, international revenues supported the revised outlook. The stock has seen volatility, with a 50.86% 90-day return but a 32.65% YTD decline. Analysts' price targets range from $40 to $85, with a consensus of $60.40, suggesting a 3% overvaluation.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning INSP (Inspire Medical Systems, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent INSP coverage spans earnings, financial news and market movers.
Analyst price‑target increase signals higher near‑term upside.
Positive earnings surprise and guidance lift likely support short‑term upside.
Earnings beat and higher guidance may support short‑term upside but valuation remains contested.
The piece frames INSP as trading above a narrative fair value despite guidance updates, emphasizing reimbursement and adoption risks.
Guidance raise with large reimbursement headwinds implies near-term margin pressure but improved visibility, shifting the risk balance toward payer/coding execution and CMS rate proposals.
AlphAI scores every news story that mentions INSP with an AI model for sentiment and relevance, and aggregates insider trades from Inspire Medical Systems, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Inspire Medical Systems (INSP) stock rose 7.4% after Stifel raised its price target to $80.00, citing positive sentiment. Shares later cooled to $70.71, up 3.8%. The company's shares are volatile, with significant moves tied to regulatory changes and analyst upgrades. INSP is down 23.4% YTD and 50.9% off its 52-week high.
2 min readInspire Medical Systems (NYSE:INSP), Cybin (NASDAQ:HELP), and Aveanna Healthcare (NASDAQ:AVAH) are flagged as overbought with RSI values above 70. INSP reported strong Q2 results and raised FY26 guidance, while AVAH received an Overweight rating and higher price target from Barclays. All three stocks showed significant gains over the past month.
2 min readInspire Medical Systems (INSP) reported Q2 2026 adjusted EPS of $0.14, beating estimates, and raised its 2026 revenue and earnings guidance. Despite U.S. coding and reimbursement challenges, international revenues supported the revised outlook. The stock has seen volatility, with a 50.86% 90-day return but a 32.65% YTD decline. Analysts' price targets range from $40 to $85, with a consensus of $60.40, suggesting a 3% overvaluation.
2 min readSimply Wall St reports Inspire Medical Systems (INSP) released Q2 2026 results and updated full-year guidance on Aug 3, alongside a share repurchase update. The article cites INSP’s $57.10 close, a consensus analyst price target of $52.17, with a range from $39 to $65, and discusses valuation multiples and risks tied to reimbursement and Inspire V adoption.
6 min readInspire Medical Systems (NYSE:INSP) reported Q2 2026 revenue of $200.6M, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Gross margin rose to 85.5%. Full-year revenue guidance was raised to $835M-$875M, with an estimated $40M Q2 and $120M-$130M full-year reimbursement headwind.
7 min readInspire Medical Systems (INSP) disclosed a Schedule 13G/A showing a group led by Soleus Capital Master Fund, L.P. and related entities, plus Guy Levy, reports beneficial ownership of 1,931,436 shares, or 6.7% of INSP common stock. The filing cites 28,910,375 shares outstanding as of July 30, 2026, with shared voting and dispositive power.
2 min readInspire Medical Systems (INSP) reported Q2 results with improved coding clarity and cost discipline, citing outperformance versus Wall Street expectations despite year-on-year revenue decline. Revenue was $200.6M vs $194.7M estimate, adjusted EPS $0.14 vs -$0.25, and adjusted EBITDA $38.9M vs $27.68M. Full-year revenue guidance was raised to $855M and adjusted EPS to $1.25 at the midpoint.
6 min readInspire Medical Systems (INSP) reported Q2 2026 revenue of $200.58M, down from $217.09M, with net income of $0.314M versus a $3.59M net loss a year earlier. For full-year 2026, management raised revenue guidance to $835M–$875M and updated diluted EPS to a loss of $0.42 to earnings of $0.17.
6 min readDeutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
3 min readInvesting.com says Q2 earnings season lifted US stocks, with the S&P 500 recording a record close and the Dow topping 54,000. It highlights AI-selected picks and cites recent results for Gartner (IT), Inspire (INSP), Arm (ARM), First Solar (FSLR), and Intel (INTC), including EPS and revenue beats and raised guidance, plus valuation and margin metrics for Gartner and Arm.
7 min read
